In the latest trading session, Pfizer (PFE) closed at $24.88, marking a -1.31% move from the previous day. The stock trailed the S&P 500, which registered a daily gain of 0.46%. At the same time, the ...

Morgan Stanley (MS) has issued a less optimistic outlook on the performance of the shares of American pharmaceutical giant ...

Turning to Wall Street, the analysts’ consensus rating for Pfizer is Hold, based on five Buy, 11 Hold, and a single Sell ...

Pfizer Inc. (NYSE:PFE)’s shares are down by 5.90% year-to-date, and December has been a tumultuous month for them.

The latest trading day saw Pfizer (PFE) settling at $25.78, representing a +1.78% change from its previous close.

Pfizer stock offers 30% upside with strong non-COVID franchises, margin expansion, and pipeline potential. Click here to read my latest analysis of PFE stock.

Pfizer to provide full-year 2026 financial guidance on Tuesday. BofA analyst expects flat growth, reiterates Neutral rating.

Pfizer PFE recently announced a landmark deal with the Trump administration. Per the deal, Pfizer committed to key measures aimed at lowering prescription drug costs while boosting investment in ...

Pfizer Inc. (NYSE: PFE) is one of the Cheap NYSE Stocks to Buy Now. On December 6, Pfizer Inc. (NYSE: PFE) announced results ...

Investors in Pfizer Inc (Symbol: PFE) saw new options begin trading today, for the December 5th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PFE options ...

Pfizer (PFE) is reiterated as a Buy, supported by the world's largest drug pipeline and trading below intrinsic value, despite near-term headwinds.